{"prompt": "['2016N298481_02', 'CONFIDENTIAL', '-', '205270', 'Objectives and Endpoints:', 'Objective', 'Endpoint', 'Primary', 'Mean change in Hgb between baseline', 'To compare the efficacy of daprodustat to', 'and the Evaluation Period (EP, mean', 'placebo on mean change in Hgb levels', 'over Week 24 to Week 28)', 'Principal Secondary', 'To compare the proportion of participants', '% of participants having a Hgb increase', 'achieving increases in Hgb when treated', 'of >1.0 g/dL to EP.', 'with daprodustat versus placebo.', 'To compare daprodustat to placebo for', 'Mean Change in 36-item Short Form', 'health related quality-of-life', 'health survey (SF-36) Vitality domain,', 'between baseline and Week 28', 'Safety', 'To compare the safety and tolerability of', 'Incidence and severity of adverse events', 'daprodustat to placebo', '(AEs) and serious adverse events (SAEs)', 'including AEs of special interest and', 'adjudicated Major Adverse', 'Cardiovascular Events (MACE)', '(composite of all-cause mortality, non-fatal MI', 'and non-fatal stroke)', 'Reasons for discontinuation of study', 'treatment', 'Absolute values and changes from', 'baseline in laboratory parameters, blood', 'pressure (BP) and heart rate (HR)', 'Overall Design:', 'This is a 28-week, randomized, double-blind, placebo-controlled, parallel-group, multi-', 'center Phase 3 study in participants with anemia associated with CKD who are not on', 'dialysis. This study will enroll participants with renal anemia who have a HemoCue Hgb', '8.5 to 10.0 g/dL, inclusive, as measured by a point-of-care Hgb analyser (HemoCue).', 'These participants will also have limited history of IV iron use and are rhEPO na\u00efve prior', 'to screening and randomization.', 'Study treatment doses for participants in both treatment arms will be titrated based upon', 'HemoCue Hgb. Dose modifications for all participants will follow a protocol-specified', 'dose adjustment algorithm to achieve and maintain Hgb within the target range of 11.0 to', '12.0 g/dL, inclusive. Dose changes will be made programmatically by the Interactive', 'Response Technology (IRT) system for both randomized treatment arms.', '11']['2016N298481_02', 'CONFIDENTIAL', '205270', 'A rescue algorithm is provided to minimize participants having an inadequate response to', 'treatment of their anemia after a fixed period of time and to enable rescue therapy to be', 'provided to the participants based on local clinical practice.', 'A Clinical Events Committee (CEC) will adjudicate any event suspected to be a major', 'adverse cardiovascular event (MACE).', 'Number of Participants:', 'Approximately 1200 participants will be screened to achieve approximately 600', 'randomized and approximately 540 evaluable participants for an estimated total of 270', 'evaluable participants per treatment arm.', 'Treatment Groups and Duration:', 'Participants will be randomized 1:1 to receive either daprodustat or matching placebo', 'tablets, administered once daily.', 'This study includes a 4-week Screening period, a 28-week Treatment period, and a 4-', 'week Follow-up period. The total duration of study participation for each participant will', 'be approximately 36 weeks.', '12']['2016N298481_02', 'CONFIDENTIAL', '205270', '2.', 'SCHEDULE OF ACTIVITIES (SOA)', 'Table 1', 'Schedule of Activities', 'Protocol activity (visits 1 week)', 'Treatment Period: Day 1 through Week 28', 'Screening', 'Follow-up Visit', '(Note: All visit timings are relative to Day 1)', 'Week -41', 'Screening', 'Day 1', 'Week 2', 'Full study visit', 'Abbreviated study visit', '(4 weeks post', 'Week 28', 'Unscheduled', 'Week -2', 'Week 4, 16', 'Week 8, 12, 20, 24', 'treatment)', 'Informed Consent', 'X', 'Assess eligibility', 'X', 'IRT system call', 'X', 'X', 'X17', 'X', 'X', 'X', 'X17', 'X', 'Birth Year (demography)', 'History: medical, hospitalization, height,', 'X', 'X2', 'weight', 'SBP/DBP and HR 3', 'X', 'X (triplicate)', 'X', 'X(triplicate)', 'X', 'X', 'ECG', 'X4', 'X', 'Ultrasound of kidney and adrenal glands (if', 'X5', 'X15', 'able to be visualized)', 'Anemia therapy6', 'X', 'X', 'X', 'X', 'X', 'X', 'Rescue medication7', 'X', 'X', 'X', 'X', 'Review concomitant medications', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Females only: estradiol and FSH (if', 'X', 'required and only for women whose', 'menopausal status is unclear)', 'FRP only: urine pregnancy test8', 'X', 'X', 'X', 'X16', 'X', 'X', 'HemoCue Hgb', 'X', 'X (Duplicates', 'X', 'X', 'X', 'X', 'X', 'Hematology 10', 'X', 'X', 'Hgb only', 'X', 'X', 'X', 'Clinical chemistry 10', 'X', 'X', 'X', 'X', 'X', 'X', 'Iron Panel 10', 'X', 'X11', 'X', 'X', 'X', 'Hepcidin', 'X', 'X', 'X', 'Lipids (non-fasting)', 'X', 'X', 'hsCRP', 'X', 'X', 'Distribution of participant reminder tool12', 'X', 'Adverse Event Assessment', 'X13', 'X13', 'X', 'X', 'X', 'X', 'X', 'X', 'X', '13']\n\n###\n\n", "completion": "END"}